Table 4.
Characteristics in patients according to bloodstream infections.
| Variables | Total = 122 (Number, %) |
Without BSIs = 87 (Number, %) |
BSIs = 35 (Number, %) |
p |
|---|---|---|---|---|
| Sex (male) | 59 (48.4) | 42 (48.3) | 17 (48.6) | 1.000 |
| Age, years (median, IQR) | 61.0 (47.0–70.0) | 60.0 (46.0–68.0) | 62.0 (47.5–71.5) | 0.274 |
| AML type at diagnosis | 0.011 | |||
| De novo/MRC | 97 (79.5) | 70 (80.4) | 27 (77.1) | |
| Secondary | 21 (17.2) | 15 (17.2) | 6 (17.1) | |
| Therapy-related | 4 (3.3) | 2 (2.3) | 2 (5.7) | |
| AML status at initiation of VEN-based therapy |
0.573 | |||
| Newly diagnosed | 39 (32.0) | 26 (29.9) | 13 (37.1) | |
| Refractory/relapsed | 83 (68.0) | 61 (70.1) | 22 (62.9) | |
| AML risk group | 0.328 | |||
| Favorable | 25 (20.5) | 15 (17.2) | 10 (28.6) | |
| Moderate | 46 (37.7) | 33 (37.9) | 13 (37.1) | |
| Poor | 51 (41.8) | 39 (44.8) | 12 (34.3) | |
| Combination agents | 0.103 | |||
| Decitabine | 113 (92.6) | 80 (92.0) | 33 (94.3) | |
| Azacitidine | 6 (4.9) | 6 (6.9) | 0 (0.0) | |
| Low-dose cytarabine | 3 (2.5) | 1 (1.1) | 2 (5.7) | |
| Overall response | 0.133 | |||
| CR + CRi | 56 (45.9) | 42 (48.3) | 14 (40.0) | |
| MLFS | 11 (9.0) | 5 (5.7) | 6 (17.1) | |
| Non response | 51 (41.8) | 36 (41.4) | 15 (42.9) | |
| Not available | 4 (3.3) | 4 (4.6) | 0 (0.0) | |
| Steroid use before BSI developed | 9 (7.4) | 3 (3.4) | 6 (17.1) | 0.025 |
| Overall mortality | 53 (43.4) | 38 (43.7) | 15 (42.9) | 1.000 |
AML: acute myeloid leukemia; BSIs: bloodstream infections; CR: complete recovery; CRi: complete recovery with incomplete hematologic recovery; IQR: interquartile range; MLFS: morphologic leukemia free state; MRC: myelodysplasia-related changes; VEN: venetoclax.